HC Wainwright reiterated their buy rating on shares of Dynavax Technologies (NASDAQ:DVAX) in a report released on Thursday, AnalystRatings.com reports.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.
Other equities research analysts also recently issued reports about the stock. ValuEngine upgraded shares of Dynavax Technologies from a sell rating to a hold rating in a research note on Thursday, August 1st. Zacks Investment Research downgraded shares of Dynavax Technologies from a buy rating to a hold rating in a research note on Tuesday, October 15th. Cantor Fitzgerald upgraded shares of Dynavax Technologies from a neutral rating to an overweight rating and set a $20.00 target price for the company in a research note on Wednesday, July 10th. William Blair reiterated a buy rating on shares of Dynavax Technologies in a research note on Friday, August 16th. Finally, BidaskClub upgraded shares of Dynavax Technologies from a hold rating to a buy rating in a research note on Thursday, October 24th. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The company presently has an average rating of Buy and an average target price of $12.63.
Shares of DVAX traded up $0.19 during trading hours on Thursday, reaching $5.26. The stock had a trading volume of 1,426,300 shares, compared to its average volume of 1,330,133. The firm has a 50-day moving average of $4.39 and a 200 day moving average of $4.54. Dynavax Technologies has a 52 week low of $2.60 and a 52 week high of $12.77. The company has a quick ratio of 3.47, a current ratio of 4.30 and a debt-to-equity ratio of 19.95. The company has a market cap of $349.23 million, a P/E ratio of -2.06 and a beta of 0.50.
Dynavax Technologies (NASDAQ:DVAX) last issued its earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.40) by ($0.10). Dynavax Technologies had a negative net margin of 781.10% and a negative return on equity of 304.71%. The firm had revenue of $10.58 million during the quarter, compared to analyst estimates of $10.31 million. During the same quarter last year, the business posted ($0.65) earnings per share. The company’s revenue for the quarter was up 624.7% on a year-over-year basis. As a group, equities analysts expect that Dynavax Technologies will post -1.93 earnings per share for the current year.
In related news, Director Francis Cano purchased 16,667 shares of the stock in a transaction on Monday, August 12th. The shares were purchased at an average cost of $3.00 per share, with a total value of $50,001.00. Following the acquisition, the director now directly owns 118,484 shares in the company, valued at $355,452. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 4.90% of the company’s stock.
A number of institutional investors have recently added to or reduced their stakes in DVAX. Marshall Wace LLP raised its holdings in Dynavax Technologies by 225.0% in the 1st quarter. Marshall Wace LLP now owns 16,449 shares of the biopharmaceutical company’s stock valued at $120,000 after acquiring an additional 11,387 shares during the period. Chicago Capital LLC raised its holdings in Dynavax Technologies by 15.5% in the 2nd quarter. Chicago Capital LLC now owns 2,937,266 shares of the biopharmaceutical company’s stock valued at $11,720,000 after acquiring an additional 393,124 shares during the period. Rhenman & Partners Asset Management AB raised its holdings in Dynavax Technologies by 333.1% in the 2nd quarter. Rhenman & Partners Asset Management AB now owns 1,234,335 shares of the biopharmaceutical company’s stock valued at $4,925,000 after acquiring an additional 949,335 shares during the period. Wedbush Securities Inc. bought a new position in Dynavax Technologies in the 2nd quarter valued at about $42,000. Finally, DekaBank Deutsche Girozentrale increased its holdings in shares of Dynavax Technologies by 32.3% during the second quarter. DekaBank Deutsche Girozentrale now owns 532,000 shares of the biopharmaceutical company’s stock worth $2,054,000 after purchasing an additional 130,000 shares during the period. 83.08% of the stock is currently owned by hedge funds and other institutional investors.
About Dynavax Technologies
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older.
Featured Article: What is the Consumer Price Index (CPI)?